Tom Menzies
Medical Statistician
Also affiliated: University of Leeds (2020–2023); University Hospitals Birmingham NHS Foundation Trust (2023); Leeds Teaching Hospitals NHS Trust (2023); Leeds Trinity University (2022); Institute of Cancer Research (2023); Cancer Research UK Clinical Trials Unit (2021–2023); Lancaster University (2021–2022); University of Birmingham (2021–2023)
Faculty Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Tom Menzies' research focuses on the statistical analysis of multiple myeloma patient data, particularly concerning treatment outcomes and prognostic factors. His work has investigated the significance of minimal residual disease after autologous stem-cell transplant and the impact of lenalidomide maintenance therapy. Menzies has also explored sex differences in multiple myeloma biology and clinical outcomes, analyzing data from large patient cohorts such as the Myeloma XI Trial.
His publications address optimal durations for lenalidomide maintenance and the incidence of second primary malignancies in patients receiving this treatment. Menzies' research also includes evaluating the addition of other agents, like vorinostat, to treatment regimens and examining clinical characteristics of specific myeloma subtypes, such as IgD myeloma. He has also contributed to methodological research, including comparisons of aggregation functions in multi-criteria decision analysis for drug benefit-risk assessment.
Metrics
- h-index: 8
- Publications: 20
- Citations: 274
Selected Publications
-
Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry (2023)
Collaboration Network
Top Collaborators
- Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry
- Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry
- Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry
- Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry
- Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry
- Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry
- Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry
- Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry
- Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry
- Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry
- Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry
- Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry
- Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry
Similar Researchers
Based on overlapping research topics